Cryptococcal meningitis in patients with the acquired immunodeficiency syndrome

Pharmacotherapy

Volumn 16, Issue 4, 1996, Pages 547-561

  Zeind, Caroline S ^a   Cleveland, Kerry O ^b   Menon, Madhavi ^c   Brown, James R ^c   Solomon, David K ^c  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b Division of Infectious Diseases   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; FLUCONAZOLE; FLUCYTOSINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; CELLULAR IMMUNITY; CLINICAL FEATURE; DRUG EFFICACY; FEMALE; FUNGAL MENINGITIS; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PATHOGENESIS; PREVALENCE; PROPHYLAXIS; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; FLUCONAZOLE; HIV; HUMANS; ITRACONAZOLE; MENINGITIS, CRYPTOCOCCAL;

EID: 0029818634     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (127)

1. Graybill JR. Cryptococcus neoformans. In: Gorbach SL, Bartlett JG, Blackow NR, eds. Infectious diseases. Philadelphia: WB Saunders, 1992:1896.
2. Fraser DW, Ward JI, Ajello L, et al. Aspergillosis and other systemic mycoses. JAMA 1979;242(15):1631-5.
3. Levitz SM, The ecology of Cryptococcus neoformans and the epidemiology of cryptococcosis. Rev Infect Dis 1991;13:1163-9.
4. Littman ML, Walter JE. Cryptococcosis: current status. Am J Med 1968;45:922-32.
5. Butler WT, Alling DW, Spickard A, et al. Diagnostic and prognostic value of clinical and laboratory findings in cryptococcal meningitis. N Engl J Med 1964;270:59-67.
6. Lewis JL, Rabinovich S. The wide spectrum of cryptococcal infections. Am J Med 1972;53:315-22.
7. Graybill JR, Alford RH. Cell-mediated immunity in cryptococcosis. Cell Immunol 1974;14:12-21.
8. Schimpff SC, Bennett JE. Abnormalities in cell-mediated immunity in patients with Cryptococcus neoformans infection. J Allergy Clin Immunol 1975;55:430-41.
9. Henderson DK, Bennett JE, Huber MA. Long-lasting, specific immunologic unresponsiveness associated with cryptococcal meningitis. J Clin Invest 1982;69:1185-90.
10. Dismukes WE. Management of cryptococcosis. Clin Infect Dis 1993;17(suppl 2):S507-12.
11. Bennett JE, Dismukes WE, Duma RJ, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med 1979;301:126-31.
12. Dismukes WE, Cloud G, Gallis HA, et al. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med 1987;317:334-41.
13. Diamond RD. Cryptococcus neoformans. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases, 4th ed. New York: Churchill Livingstone, 1995:2331-40.
14. Powderly WG. Therapy for cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1992;14(suppl 1):S54-9.
15. Holmberg K, Meyer R. Fungal infections in patients with AIDS and AIDS-related complex. Scand J Infect Dis 1986;18:179-92.
16. Dismukes WE. Cryptococcal meningitis in patients with AIDS. J Infect Dis 1988;157:624-8.
17. Mitchell DH, Sorrell TC, Allworth AM, et al. Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcome. Clin Infect Dis 1995;20: 611-16.
18. Chuck SL, Sande MA. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N Engl J Med 1989;321:794-9.
19. Crowe SM, Carlin JB, Stewart KI, et al. Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons. J Acquir Immune Defic Syndr 1991;4:770-6.
20. Nightingale SD, Cal SX, Peterson DM, et al. Primary prophylaxis with fluconazole against systemic fungal infections in HIV-positive patients. AIDS 1992;6:191-4.
21. Powderly WG. Cryptococcal meningitis and AIDS. Clin Infect Dis 1993;17:837-42.
22. Nightingale SD, Parks JM, Pounders SM, et al. Disseminated histoplasmosis in patients with AIDS. South Med J 1990;83(6):624-30.
23. Zuger A, Louie E, Holzman RS, et al. Cryptococcal disease in patients with the acquired immunodeficiency syndrome: diagnostic features and outcome of treatment. Ann Intern Med 1986;104:234-40.
24. Eng RH, Bishburg E, Smith SM, et al. Cryptococcal infections in patients with acquired immune deficiency syndrome Am J Med 1986;81:19-23.
25. Kovacs JA, Kovacs AA, Polis M, et al. Cryptococcosis in the acquired immunodeficiency syndrome. Ann Intern Med 1985;103:533-8.
26. Beyt BE Jr, Waltman SR. Cryptococcal endophthalmitis after corneal transplantation. N Engl J Med 1978;298:825-6.
27. Ooi BS, Chen BTM, Lim CH, et al. Survival of a patient transplanted with a kidney infected with Cryptococcus neoformans. Transplantation 1971;11(4):428-9.
28. Glaser JB, Garden A. Inoculation of cryptococcosis without transmission of the acquired immunodeficiency syndrome [letter]. N Engl J Med 1985;313:266.
29. Bhattacharjee AK, Bennett JE, Glaudemans CPJ. Capsular polysaccharides of Cryptococcus neoformans. Rev Infect Dis 1984;6:619-24.
30. Kwon-Chung KJ, Bennett JE. Epidemiologic differences between the two varieties of Cryptococcus neoformans. Am J Epidemiol 1984;120:123-30.
31. Rippon JW. Medical mycology The pathogenic fungi and the pathogenic actinomycetes, 3rd ed. Philadelphia: WB Saunders, 1988:582-609.
32. Denton JF, DiSalvo AF. The prevalence of Cryptococcus neoformans in various natural habitats. Sabouraudia 1968;6:213-17.
33. Ruiz A, Velez D, Fromtling RA. Isolation of saprophytic Cryptococcus neoformans from Puerto Rico: distribution and variety. Mycopathologia 1989;106:167-70.
34. Ellis DH, Pfeiffer TJ. Natural habitat of Cryptococcus neoformans var. gattii. J Clin Microbiol 1990;28:1642-4.
35. Pfeiffer TJ, Ellis DH. Environmental isolation of Cryptococcus neoformans var. gattii from Eucalyptus tereticornis. J Med Vet Mycol 1992;30:407-8.
36. Pinner RW, Hajjeh RA, Powderly WG. Prospects for preventing cryptococcosis in persons infected with human immunodeficiency virus. Clin Infect Dis 1995;21(suppl 1):S103-7.
37. Perfect JR. Cryptococcosis. Infect Dis Clin North Am 1989;3:77-102.
38. Henderson DK, Edwards JE Jr, Dismukes WE, et al. Meningitis produced by different serotypes of Cryptococcus neoformans [abstr 11]. In: Programs and abstracts of the 21st Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1981:315.
39. Speed BR. The epidemiology of cryptococcosis in Victoria [abstr]. Aust N Z J Med 1990;20(suppl 1):435.
40. Rozenbaum R, Goncalves AJR. Clinical epidemiological study of 171 cases of cryptococcosis. Clin Infect Dis 1994;18:369-80.
41. Speed B, Dunt D. Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. Clin Infect Dis 1995;21:28-34.
42. Neilson JB, Fromtling RA, Bulmer GS. Cryptococcus neoformans: size range of infectious particles from aerosolized soil. Infect Immun 1977;17:634-8.
43. McDonnell JM, Hutchins GM. Pulmonary cryptococcosis. Hum Pathol 1985;16:121-8.
44. Lee BL, Tauber MG. Cryptococcosis. In: Cohen PT, Sande MA, Volberding PA, eds. The AIDS knowledge base, 2nd ed. Boston: Little, Brown, 1994:6.8-1-6.8-10.
45. Clark RA, Greer D, Atkinson W, et al. Spectrum of Cryptococcus neoformans infection in 68 patients infected with human immunodeficiency virus. Rev Infect Dis 1990;12(5):768-77.
46. Diamond RD, Root RK, Bennett JE. Factors influencing killing of Cryptococcus neoformans by human leukocytes in vitro. J Infect Dis 1972;125(4):367-76.
47. Bender BS, Davidson BL, Kline R, et al. Role of the mononuclear phagocyte system in the immunopathogenesis of human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Rev Infect Dis 1988;10: 1142-54.
48. Wagner RP, Levitz SM, Tabuni A, et al. HIV-1 envelope protein (gp120) inhibits the activity of human bronchoalveolar macrophages against Cryptococcus neoformans. Am Rev Respir Dis 1992;146:1434-8.
49. Levy RM, Bredesen DE, Rosenblum ML. Neurological manifestations of the acquired immunodeficiency syndrome (AIDS): experience at UCSF and review of the literature. J Neurosurg 1985;62:475-95.
50. Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med 1992;326(2):83-9.
51. Sabetta JR, Andriole VT. Cryptococcal infection of the central nervous system. Med Clin North Am 1985;69(2):333-44.
52. Fujita NK, Reynard M, Sapico FL, et al. Cryptococcal intracerebral mass lesions. The role of computed tomography and nonsurgical management. Ann Intern Med 1981;94: 382-8.
53. Larsen RA, Bozzette S, McCutchan JA, et al. Persistent Cryptococcus neoformans infection of the prostate after successful treatment of meningitis. Ann Intern Med 1989;111:125-8.
54. Spitzer ED, Spitzer SG, Freundlich LF, et al. Persistence of initial infection in recurrent Cryptococcus neoformans meningitis. Lancet 1993;341:595-6.
55. Staib F, Seibold M, L'age M. Persistence of Cryptococcus neoformans in seminal fluid and urine under itraconazole treatment. The urogenital tract (prostate) as a niche for Cryptococcus neoformans. Mycoses 1990;33:369-73.
56. Arnold HL, Odom RB, James WD, eds. Diseases due to fungi and yeast. In: Andrews' diseases of the skin: clinical dermatology. Philadelphia: WB Saunders, 1990:367-8.
57. Resnick SD. Subcutaneous and systemic fungal infections. In: Sams WM Jr, Lynch PJ, eds. Principles and practice of dermatology. New York: Churchill Livingstone, 1990:158.
58. Sulica RL, Kelly J, Berberian BJ, et al. Cutaneous cryptococcosis with molluscum contagiosum coinfection in a patient with the acquired immunodeficiency syndrome. Cutis 1994;53:88-90.
59. White MH, Armstrong D. Cryptococcosis. Infect Dis Clin North Am 1994;8(2):383-98.
60. Stockman L, Roberts GD. Specificity of the latex test for cryptococcal antigen: a rapid, simple method for eliminating interference factors. J Clin Microbiol 1982;16(5):965-7.
61. Eng RH, Person A. Serum cryptococcal antigen determination in the presence of rheumatoid factor. J Clin Microbiol 1981;14(6):700-2.
62. Hamilton JR, Noble A, Denning DW, et al. Performance of Cryptococcus antigen latex agglutination kits on serum and cerebrospinal fluid specimens of AIDS patients before and after pronase treatment. J Clin Microbiol 1991;29:333-9
63. McManus EF, Jones JM. Detection of a Trichosporon beigelii antigen cross-reactive with Cryptococcus neoformans capsular polysaccharide in serum from a patient with disseminated Trichosporon infection. Clin Microbiol 1985;21:681-5.
64. Powderly WG, Cloud GA, Dismukes WE, et al. Measurement of cryptococcal antigen in serum and cerebrospinal fluid: value in the management of AIDS-associated cryptococcal meningitis. Clin Infect Dis 1994;18:789-92.
65. Diamond RD, Bennett JE. Prognostic factors in cryptococcal meningitis. A study in 111 cases. Ann Intern Med 1974;80:176-81.
66. Larsen RA, Leal MAE, Chan LS. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. Ann Intern Med 1990;113:183-7.
67. Powderly WG, Saag MS, Cloud GA, et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 1992;326:793-8.
68. Bloomfield N, Gordon MA, Elmendorf DF. Detection of Cryptococcus neoformans antigen in body fluids by latex particle agglutination. Proc Soc Exp Biol Med 1963;114:64.
69. Desmet P, Kayembe KD, De Vroey C. The value of cryptococcal serum antigen screening among HIV-positive/AIDS patients in Kinshasa, Zaire. AIDS 1989;3:77-8.
70. Hoffman S, Stenderup J, Mathiesen LR. Low yield of screening for cryptococcal antigen by latex agglutination assay on serum and cerebrospinal fluid from Danish patients with AIDS or ARC. Scand J Infect Dis 1991;23:697-702.
71. Denning DW, Armstrong RW, Lewis BH, et al. Elevated cerebrospinal fluid pressures in patients with cryptococcal meningitis and acquired immunodeficiency syndrome. Am J Med 1991;91:267-72.
72. Mathews VP, Alo PL, Glass JD, et al. AIDS-related CNS cryptococcosis: radiologic pathologic correlation. Am J Neuroradiol 1992;13:1477-86.
73. Popovich MJ, Arthur RH, Helmer E. CT of intracranial cryptococcosis. Am J Neuroradiol 1990;11:139-42
74. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990;12(2):308-28.
75. Medoff G, Kobayashi GS. Strategies in the treatment of systemic fungal infections. N Engl J Med 1980;302:145-55.
76. Hamilton JD, Elliott DM. Combined activity of amphotericin B and 5-fluorocytosine against Cryptococcus neoformans in vitro and in vivo in mice. J Infect Dis 1975;131:129-37.
77. Steer PL, Marks MI, Klite PD, et al. 5-Fluorocytosine: an oral antifungal compound: a report on clinical and laboratory experience. Ann Intern Med 1972;76:15-22.
78. Roche Laboratories. Ancobon (flucytosine) package insert. Nutley, NJ; 1994.
79. Schonebeck J, Polak A, Fernex M, et al. Pharmacokinetic studies on the oral antimycotic agent 5-fluorocytosine in individuals with normal and impaired kidney function. Chemotherapy 1973;18:321-36.
80. Bennett JE. Flucytosine. Ann Intern Med 1977;86:319-22.
81. Stamm AM, Diasio RB, Dismukes WE, et al. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med 1987;83:236-42.
82. Francis P, Walsh TJ. Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin Infect Dis 1992;15:1003-18.
83. de Gans J, Portegies P, Tiessens G, et al. Itraconazole compared with amphotericin B plus flucytosine in AIDS patients with cryptococcal meningitis. AIDS 1992;6:185-90.
84. Van Der Horst C, Saag MS, Cloud GA, et al. Part 1. Randomized double blind comparison of amphotericin B plus flucytosine (AMB + FC) to AMB alone (step 1) followed by a comparison of fluconazole to itraconazole (step 2) in the treatment of acute cryptococcal meningitis in patients with AIDS [abstr 1216]. In: Programs and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco. Washington, DC: American Society for Microbiology, 1995:244.
85. Saag MS, Van Der Horst C, Cloud GA, et al. Part 2. Randomized double blind comparison of amphotericin B plus flucytosine (AMB + FC) to AMB alone (step 1) followed by a comparison of fluconazole (FLU) to itraconazole (ITRA) (step 2) in the treatment of acute cryptococcal meningitis in patients with AIDS [abstr 1217]. In: Programs and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco. Washington, DC: American Society for Microbiology, 1995:244.
86. Stern JJ, Hartman BJ, Sharkey P, et al. Oral fluconazole therapy for patients with acquired immunodeficiency syndrome and cryptococcosis: experience with 22 patients. Am J Med 1988;85:477-80.
87. Stern JJ, Pietroski NA, Buckley RM, et al. Parenteral and oral fluconazole for acute cryptococcal meningitis in AIDS: experience with thirteen patients. Ann Pharmacother 1992;26:876-82.
88. Berry AJ, Rinaldi MG, Graybill JR. Use of high-dose fluconazole as salvage therapy for cryptococcal meningitis in patients with AIDS Antimicrob Agents Chemother 1992;36:690-2.
89. Byrne WR, Wajszczuk CP. Cryptococcal meningitis in the acquired immunodeficiency syndrome (AIDS): successful treatment with fluconazole after failure of amphotericin B. Ann Intern Med 1988;108:384-5.
90. Robinson PA, Knirsch AK, Joseph JA. Fluconazole for life-threatening fungal infections in patients who cannot be treated with conventional antifungal agents. Rev Infect Dis 1990;12(suppl 3):S349-63.
91. Denning DW, Tucker RM, Hanson LH, et al. Itraconazole therapy for cryptococcal meningitis and cryptococcosis. Arch Intern Med 1989;149:2301-8.
92. Viviani MA, Tortorano AM, Pagano A, et al. European experience with itraconazole in systemic mycoses. J Am Acad Dermatol 1990;23(3, Part 2):587-93.
93. Vivani MA, Tortorano AM, Langer M, et al. Experience with itraconazole in cryptococcosis and aspergillosis. J Infect 1989;18:151-65.
94. Hostetler JS, Denning DW, Stevens DA. US experience with itraconazole in Aspergillus, Cryptococcus and Histoplasma infections in the immunocompromised host. Chemotherapy 1992;38(suppl 1):12-22.
95. Nightingale SD. Initial therapy for acquired immunodeficiency syndrome-associated cryptococcosis with fluconazole. Arch Intern Med 1995;155:538-40.
96. Larsen RA, Bozzette SA, Jones BE, et al. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1994;19: 741-5.
97. Chotmongkol V, Jitpimolmard S. Treatment of cryptococcal meningitis with combination itraconazole and flucytosine. J Med Assoc Thai 1994;77(5):253-6.
98. Cauwenbergh G. Cryptococcal meningitis: the place of itraconazole. Mycoses 1993;36:221-8.
99. Janknegt R, de Marie S, Bakker-Woudenberg I, et al. Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics. Clin Pharmacokinet 1992;23(4):279-91.
100. Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 1996;22(suppl 2):S133-44.
101. Coker RJ, Viviani M, Gazzard BG, et al. Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS. AIDS 1993;7:829-35.
102. Liposome Co. Abelcet (amphotericin B lipid complex) package insert. Princeton, NJ; 1995.
103. Sharkey PK, Graybill JR, Johnson ES, et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996;22:315-21.
104. Cleary JD. Amphotericin B formulated in a lipid emulsion. Ann Pharmacother 1996;30:409-12.
105. Moreau P, Milpied N, Fayette N, et al. Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients. J Antimicrob Chemother 1992;30: 535-41.
106. Caillot D, Reny G, Solary E, et al. A controlled trial of the tolerance of amphotericin B infused in dextrose or in intralipid in patients with haematological malignancies. J Antimicrob Chemother 1994;33:603-13.
107. Chavanet P, Garry I, Charlier N, et al. Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis. BMJ 1992;305:921-5.
108. Bartizal K, Scott T, Abruzzo GK, et al. In vitro evaluation of the pneumocandin antifungal agent L-733560, a new water-soluble hybrid of L-705589 and L-731373. Antimicrob Agents Chemother 1995;39(5):1070-6.
109. Bartizal K, Abruzzo G, Schmatz D. The pneumocandins: biological activity of the pneumocandins. In: Rippon J, Fromtling RA, eds Cutaneous fungal infections. New York: Marcel Dekker, 1993:421-55.
110. Bartizal K, Abruzzo G, Trainor C, et al. In vitro antifungal activities and in vivo efficacies of 1, 3-β-D-glucan synthesis inhibitors L-671329, L-646991, tetrahydroechinocandin B, and L-687781, a papulacandin. Antimicrob Agents Chemother 1992;36:1648-57.
111. Kurtz MB, Douglas C, Marrinan J, et al. Increased antifungal activity of L-733560, a water soluble semi-synthetic pneumocandin, is due to enhanced inhibition of cell wall synthesis. Antimicrob Agents Chemother 1994;38:2750-7.
112. Pacholok C, Lynch L, Kropp H, et al. In vitro evaluation of L-733560, a new water soluble lipopeptide hybrid of L705589 and L731373 [abstr 351]. In: Programs and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1993:184.
113. Abruzzo GK, Flattery AM, Gill CJ, et al. Evaluation of water-soluble pneumocandin analogs L-733560, L-705589, and L-731373 with mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother 1995;39:1077-81.
114. Bozzette SA, Larsen RA, Chiu J, et al. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. N Engl J Med 1991;324(9):580-4.
115. deGans J, Schattenkerk JK, van Ketel RJ. Itraconazole as maintenance treatment for cryptococcal meningitis in the acquired immune deficiency syndrome. Br Med J 1988;296:339.
116. Saag MS, Cloud GC, Graybill JR, et al. Comparison of fluconazole (FLU) versus itraconazole (ITRA) as maintenance therapy of AIDS-associated cryptococcal meningitis (CM) [abstr 1218]. In: Programs and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1995:244.
117. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995;39:1-8.
118. Boken DJ, Swindells S, Rinaldi MG. Fluconazole-resistant Candida albicans. Clin Infect Dis 1993;17:1018-21.
119. Peetermans W, Bobbaers H, Verhaegen J, et al. Fluconazole-resistant Cryptococcus neoformans var. gattii in an AIDS patient. Acta Clin Belg 1993;48:405-9.
120. Coker RJ, Harris JRW. Failure of fluconazole treatment in cryptococcal meningitis despite adequate CSF levels [letter]. J Infect 1991;23:101-3.
121. Powderly WG, Finkelstein DM, Feinberg J, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995;332(11):700-5.
122. Devi SJN, Schneerson R, Egan W, et al. Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity. Infect Immun 1991;59:3700-7.
123. Williamson PR, Bennett JE, Polis MA, et al. Immunogenicity and safety of a conjugate glucuronoxylomannan-tetanus conjugate vaccine in volunteers [abstr 56]. Clin Infect Dis 1993;17:540.
124. Mukherjee J, Pirofski L, Scharff MD, et al. Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection. Proc Natl Acad Sci USA 1993;90:3636-40.
125. Lane HC, Laughon BE, Falloon J, et al. Recent advances in the management of AIDS-related opportunistic infections. Ann Intern Med 1994;120:945-55.
126. Masur H. Management of opportunistic infections associated with HIV infection. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases, 4th ed. New York: Churchill Livingstone, 1995:1288.
127. Nelson MR, Fisher M, Cartledge J, et al. The role of azoles in the treatment and prophylaxis of cryptococcal disease in HIV infection. AIDS 1994;8:651-4.